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Abstract
Purpose The objective was to systematically review clinical
trial data on the effectsof statins on high-density lipoproteins
(HDL) and to examine the possibility that this provides
cardiovascular benefits in addition to those derived from
reductions in low-density lipoproteins (LDL).
Methods The PubMed database was searched for publica-
tions describing clinical trials of atorvastatin, pravastatin,
rosuvastatin, and simvastatin. On the basis of predefined
criteria, 103 were selected for review.
Results Compared with placebo, statins raise HDL, measured
asHDL-cholesterol(HDL-C)andapolipoproteinA-I(apoA-I);
these elevations are maintained in the long-term. In hypercho-
lesterolemia, HDL-C is raised by approximately 4% to 10%.
The percentage changes are greater in patients with low
baseline levels, including those with the common combination
of high triglycerides (TG) and low HDL-C. These effects do
not appear to be dose-related although there is evidence that,
with the exception of atorvastatin, the changes in HDL-C are
proportional to reductions in apo B-containing lipoproteins.
The most likely explanation is a reduced rate of cholesteryl
estertransferprotein(CETP)-mediatedflowofcholesterolfrom
HDL. There is some evidence that the statin effects on HDL
reduce progression of atherosclerosis and risk of cardiovascular
disease independently of reductions in LDL.
Conclusion Statins cause modest increases in HDL-C and
apo A-I probably mediated by reductions in CETP activity.
It is plausible that such changes independently contribute to
the cardiovascular benefits of the statin class but more
studies are needed to further explore this possibility.
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Introduction
It has been known for over 30 years that circulating levels
of high-density lipoprotein (HDL) are inversely associated
with the risk of atherosclerotic diseases [1]. Population
studies, in which HDL was measured as HDL-cholesterol
(HDL-C) or apolipoprotein A-I (apo A-I), have repeatedly
confirmed the strong and apparently independent relation-
ship with risk of coronary heart disease (CHD) [2–4]. A
partial understanding of HDL metabolism has emerged in
this period, particularly regarding the role of apo A-I, the
major protein component of HDL, in promoting cholesterol
efflux from foam cell macrophages of atherosclerotic
lesions [5, 6]. According to current models, HDL operates
as a dynamic system, removing excess cholesterol from
cells, transporting it to the liver for excretion, and ensuring
overall cholesterol homeostasis in the body. Recent labora-
tory evidence suggests that HDL may in addition retard
atherosclerosis through antioxidant and anti-inflammatory
actions [7, 8]. Evidence from both experimental and
population studies has led to the concept of HDL as a
protective system, mitigating the damaging effects on the
vessel wall of apo B-containing low and very-low-density
lipoproteins (LDL and VLDL). HDL is metabolically
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HDL-C levels are commonly found in subjects with
elevated serum triglycerides (TG) and VLDL, a profile that
carries a high risk of CHD [2]. Moreover, low HDL-C
levels are frequent in those with obesity, metabolic
syndrome or type 2 diabetes (T2D), conditions in which
TG metabolism is abnormal [9]. HDL levels are also
affected by some lifestyle factors such as exercise and
smoking. In addition, there are a number of important
independent genetic determinants [10].
The guidelines issued by the Adult Treatment Panel III of
the National Cholesterol Education Programme [11] identify
low HDL-C level as an important risk factor for cardiovas-
cular disease (CVD) and as a criterion for the initiation of
lifestyle changes, and use of therapeutic agents. Neverthe-
less, treatment emphasis remains firmly on reduction of
LDL-C, primarily using HMG-CoA reductase inhibitors
(statins), which very effectively reduce circulating levels of
atherogenic LDL via upregulation of LDL receptors. The
clinical success of statins confirms the epidemiological
evidence and points to elevated LDL as a direct cause of
atherosclerosis progression [12]. However, statins also
increase HDL, measured as HDL-C or apo A-I, and, based
on the strong epidemiologic evidence, it is possible that this
action may independently contribute to their benefits.
From the combined data from four large prospective
studies, Gordon et al. [13] estimated that an increment of
1 mg/dl in HDL-C is associated with a 2–3% lower risk of
CHD. Thus, a relatively modest statin-mediated effect on
HDL-C, for example, an increase of 10% that is possible
with statins [14], might provide important protection from
CVD in addition to the undoubted benefits of LDL
reduction. However, extrapolation from epidemiology to
putative benefits of drug therapy requires caution. Support
for the concept of HDL-raising by drugs comes from
prospective trials of fibrates and of nicotinic acid, two drug
types with substantial effects on HDL and VLDL metabo-
lism [15–18], and also from early clinical work with
infusions of apo A-I in liposomes where dramatic reductions
in coronary atheroma have been observed [19]. In contrast,
recent trials of torcetrapib, an inhibitor of cholesteryl ester
transfer protein (CETP) that induces substantial increases in
HDL-C and apo A-I failed to show any benefit on
atherosclerosis [20–22]. It is possible that the plasma
concentrations of HDL-C or apo A-I may not always reflect
the protective activity of the HDL system. It is important to
consider both the magnitude of effect on HDL level and the
mechanism by which it is achieved. Two explanations have
been proposed for the effects of statins on HDL. In cell
experiments, inhibition of HMG-CoA reductase by statins
was shown to increase peroxisome-proliferator receptor
activator-alpha (PPARα) activity and, like fibrates, to elevate
the hepatic synthesis of apo A-I [23]. Such an effect would
be expected to increase the formation of HDL precursor
particles. A second explanation revolves around the meta-
bolic relationship between HDL and TG-rich atherogenic
lipoproteins. Guerin et al. [24]s h o w e dt h a ta t o r v a s t a t i n
reduced circulating levels of CETP, and also importantly the
rate of CETP-mediated CE transfer from HDL to VLDL
secondary to reduction in the latter. Statins, however, are not
known to be direct inhibitors of CETP.
With statins, elevations in HDL-C range between 3%
and 15%. These are relatively modest increases compared
with agents such as nicotinic acid, fibrates, and the recently
developed CETP inhibitors. However, given the widespread
use of statins and the putative benefit of HDL elevation, it
is important to thoroughly assess this aspect of statin action.
In this review we consider: (1) data from placebo-controlled
trials to confirm that statins have real effects on HDL, (2)
how effects on HDL compare between statins when
administered at recommended starting doses, (3) dose-
related effects of statins on HDL and comparative data at
the highest prescribed doses, (4) the effects of statins in
patients with mixed hyperlipidemia and diabetes, and (5)
the longer-term effect of statins on HDL and evidence
linking this to clinical benefit.
Methods
For this review, searches were conducted for publications
that appeared on the PubMed database up to the end of
2007 that describe clinical trials of atorvastatin, pravastatin,
rosuvastatin, and simvastatin; this generated 2,630 citations.
The studies varied widely with respect to populations
studied, treatment duration, and design. Selection from the
total was based on predefined criteria. Only articles that
provided HDL data from randomized clinical trials were
included (almost 50% of the total). Sub studies were not
included unless they were particularly pertinent. Since
variability in change in HDL parameters with statin
treatment greatly exceeds that for LDL, only studies that
utilized ≥50 patients per group in parallel design or ≥30 in a
crossover design were included. In addition, only those
studies with a dietary lead-in period ≥2 weeks (given the
influence of diet on HDL levels) and a treatment period
≥6 weeks were included; 47% of studies were excluded on
these design criteria.
Finally, we considered the method by which HDL-C had
been measured. The most commonly used assays are those
in which it is measured after apo B-containing lipoproteins
are precipitated from plasma with polyvalent anion and
divalent metal cation; one such is the reference method of
the US Center for Disease Control. Recently developed
homogeneous assays employ a variety of reagents to block
apo B-containing lipoproteins, allowing assay only of
322 Cardiovasc Drugs Ther (2008) 22:321–338HDL-C. However, questions remain as to the specificity of
these assays under contrasting conditions of high and low
LDL levels as typically observed in statin trials [25]. Only
those studies were included in which HDL-C was con-
firmed in the publication or after enquiry to the lead author
as having been measured using a precipitation method.
Fifteen percent of the remaining citations were excluded on
this basis leaving 103 publications that conformed to our
criteria; these form the basis of our review.
Effects of statins on HDL: evidence
from placebo-controlled trials
Most clinical trials of statins were designed with LDL-
cholesterol (LDL-C) as the primary endpoint and conducted
in patients with hypercholesterolemia, excluding those with
very high TG. Usually the study populations had normal
HDL-C levels on average and were treated for at least 6
weeks. In the placebo-controlled trial of Hunninghake et al.
[26], a study was made of the rate of change of lipoprotein
parameters in response to a range of doses of pravastatin.
Patients were randomized following dietary stabilization
and then treated for 12 weeks. In the pravastatin groups,
HDL-C increased from baseline, reached maximal levels at
4 weeks and remained steady thereafter, whilst in the
placebo group it was almost unchanged. At week 12,
pravastatin had increased HDL-C by 6–7% from baseline,
compared with 1% for placebo. The observed time course
of the HDL-C increases with pravastatin paralleled the
reductions in both LDL-C and TG, suggesting a mechanis-
tic relationship between the changes. A treatment period of
≥6 weeks (one of our selection criteria) appears adequate
for assessing the effects of statins on HDL-C.
Statin-induced effects on HDL are relatively small com-
pared withthose of LDL and, asa result, mostclinical trialsof
statins are underpowered with respect to HDL parameters. In
this review, the emphasis is initially placed therefore on those
studies with the largest sample sizes. To allow comparison
between trials, data relating to errors of the estimates for
changes in HDL-C and apo A-I have been converted to 95%
confidence intervals.Figure 1 describes the findings from the
four largest placebo-controlled statin trials, which measured
both HDL-C and apo A-I and reported the errors of the
estimates of change. All four trials were in patients with
primary hypercholesterolemia with TG levels <450 mg/dl.
Patients were randomized in a parallel design following a
dietary lead period ≥2 weeks. In two of the studies [29, 30],
the errors of estimates are reported only for the pooled 10–
80 mg simvastatin dose groups. These pooled dataare shown
inFig.1 to allow comparison with placebo. It is apparent that
the percentage changes in HDL-C in the statin-treated groups
are consistently greater than placebo; the lack of overlap in
the 95% confidence limits suggests real drug responses. A
similarly large study of pravastatin 20 mg [31]f o u n da7 %
increase in HDL-C compared with placebo (p<0.001). Over
the four trials the magnitude of effect on apo A-I was
consistently less than on HDL-C, and not statistically
different from placebo in two of them. This suggests that
statins change HDL to a more cholesterol-rich form.
Eight other smaller placebo-controlled trials (n≤106) in
hypercholesterolemic patients of duration ≤6m o n t h sa l s o
fitted our selection criteria [32–39]. In 14 of the 15 statin
dose groups comprising these studies, the mean change in
HDL-C was numerically greater than in the corresponding
placebo group. This was also the case for apo A-I in all nine
groups in which it was measured. However, differences vs.
placebo were not always significant, perhaps reflecting
smaller group sizes. Similar findings were reported in a
12-week study in patients of African-American descent,
where the HDL-C response to pravastatin was numerically
greater but not significantly different from placebo [40].
It is important to consider whether statin-induced
changes in HDL, like those in LDL, can be maintained
over the long term. Keech et al. [41] measured the effects of
simvastatin 20 and 40 mg over 3 years in patients
considered to be at risk of CHD. Although this study did
not include a dietary lead-in period, changes from baseline
in the placebo group were minor. In the combined
simvastatin groups, significant increases in HDL-C of 8–
10% vs. placebo were maintained over 3 years while
increases in apo A-I were also significant vs. placebo (5%
measured up to 2 years only). HDL-C and occasionally also
apo A-I have been monitored in large-scale placebo-
controlled studies employing atherosclerosis progression
or cardiovascular event endpoints, conducted for ≥2 years.
The HDL-C data from these trials are summarized in
Table 1. In general, the study populations were more
inclusive than in shorter-term studies. In all but one trial,
there was a positive effect on HDL-C (range, 1.5–10%)
relative to placebo. The apo A-I responses when measured
were lower and relatively variable. Data from these longer-
term trials are consistent with those of shorter lipid-
endpoint studies bearing in mind that compliance often
decreases as the duration of the study increases.
The relatively large sample sizes in outcomes studies
provide opportunities to identify factors contributing to the
HDL response and thereby deduction as to possible mecha-
nisms. In the untreated population, there is a well-established
inverse curvilinear relationship between plasma levels of TG
and HDL-C, with most variation in HDL-C being apparent at
TG levels <220 mg/dl [56]. This reflects in part the action of
CETP since high VLDL-TG levels facilitate the two-way
transfer of TG and cholesteryl ester between VLDL and
HDL. In a follow-up to the West of Scotland Coronary
Prevention Study (WOSCOPS) [47], Streja et al. [57]
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who were fully compliant (about half). Mean percent change
in the pravastatin group decreased across quintiles of
baseline HDL-C, such that the absolute increment remained
relatively constant. Independent contributors to statin-
induced change in HDL-C were alcohol intake, body mass
index, and reduction in plasma TG, all of which have
influence on plasma CETP levels and/or activity. Most likely
the reduction in cholesteryl ester transfer from HDL that
results in elevation of HDL-C is governed by the degree of
reduction in VLDL [24]. The effect of statin would be to
shift the patient’s position on the population curve relating
HDL-C to TG levels. Such a mechanism involving CETP
would be consistent with alteration of the particle size
distribution of HDL towards larger, relatively cholesterol-
rich particles that are characteristic of healthy low-risk
populations manifesting the ideal profile of low TG and
high HDL-C. Such statin-induced changes in subpopulations
of HDL have been consistently demonstrated in the studies
of Asztalos et al. [58–61].
Fig. 1 Effects of statins on a
high-density lipoprotein
cholesterol (HDL-C)a n d
b apolipoprotein A-I (apo A-I)i n
placebo-controlled studies in
hypercholesterolemic patients.
Data are shown as mean percent
change from baseline ±95%
confidence limits. Dose (mg) is
shown at the foot of each column
324 Cardiovasc Drugs Ther (2008) 22:321–338Hepatic lipase is another factor with a key role in TG
and lipoprotein metabolism. Increased hepatic lipase due
to a common polymorphism (−514 C→T) is associated
with lower levels of the larger HDL particles (HDL2)a s
well as greater numbers of small dense (more atherogenic
LDL) [62–66]. In an intervention trial with combination
lipid-lowering therapy including lovastatin [65], subjects
homozygous for this allele had the highest hepatic lipase
activity, lowest HDL2-C and the most angiographic
improvement compared to those heterozygous or lacking
the allele.
In summary, data from placebo-controlled trials in
hypercholesterolemic subjects confirm that statins cause
definite increases in HDL-C; the mechanism most likely
involves reduced transfer of cholesteryl ester from HDL to
VLDL but other factors such as hepatic lipase and other
statin-induced effects may also contribute. The data also
suggest that statin effects on HDL-C and apo A-I are
maintained over time and that a treatment period of 6 weeks
is sufficient to assess and compare different statins in this
respect.
Comparative effects of statins on HDL at recommended
starting doses
In clinical practice, most patients remain on the statin dose
first prescribed [67] so it is appropriate to first compare the
effects on HDL of statins when used at their recommended
starting doses: atorvastatin 10 or 20 mg, pravastatin 20 or
40 mg, rosuvastatin 5 or 10 mg, and simvastatin 20 or
40 mg. Figure 2 shows data from the four largest
comparative trials (n≥156 per group) conducted to date that
included these starting doses and met our criteria. Blasetto et
al. [71] reported data from five individual trials prospectively
designed for pooling into two sets (1) [29, 74, 75] and (2)
[76, 77]. All trials were of parallel design with treatment
duration ≥6 weeks, measured both HDL-C and apo A-I and
reported the errors of the estimates of percentage change.
Eligible patients included those with hypercholesterolemia, a
relatively normal HDL-C level, TG <400 mg/dl, with or
without high risk, manifest CHD or T2D.
Figure 2a shows there were no consistent differences in
HDL responses between the upper and lower starting doses
Table 1 Effects of statins on HDL-C in long-term placebo-controlled trials with atherosclerosis or cardiovascular event endpoints
Study Patient
population
Dietary
run-in
Mean BL
HDL-C
(mg/dl)
Treatment
(mg)
Duration
(year)
% change in HDL-C
vs. placebo
4S, 4S Study Group [42] CHD and TC 212–309 mg/dl Yes 46 S20–40 5 7 (mean on trial)
KAPS Salonen et al. [43] Males with LDL-C >155 mg/dl Yes 46 P40 3 3.0 (mean on trial)
PLAC-I, Pitt et al. [44] CHD and LDL-C 140–190 mg/dl Yes 41 P40 3 5 (mean on trial)
PLAC-II, Byington
et al. [45]
CHD and LDL-C 60th–90th
percentile
No 40–42 P20–40 3 −2.8 (mean on trial)
a
REGRESS, Jukema
et al. [46]
Males with CHD and normal
to moderately elevated TC
Yes 36 P40 2 9 (at 2 years)
WOSCOPS, Shepherd
et al. [47]
Men: LDL-C ≥155 mg/dl Yes 44 P40 5 5 (mean on trial)
CAIUS, Mercuri
et al. [48]
One carotid lesion and moderately
elevated LDL-C
Yes 53 P40 3 4.4 (mean on trial)
CARE, Sacks et al. [49] CHD and LDL-C 115–174 mg/dl Yes 39 P40 5 5 (mean on trial)
HPS, HPS Study
Group [50]
CHD or other occlusive vascular
or diabetes
No 41 S40 5 2.8 (mean on trial)
PROSPER, Shepherd
et al. [51]
History of or risk factors for
vascular disease, 70–82 years
Yes 50 P40 3 5 (at 3 months)
LIPID, Tonkin et al. [52] CHD and TC 155–271 mg/dl Yes 36 (median) P40 6 5 (mean in first
5 years)
ASCOT-LLA, Sever
et al. [53]
Hypertension and 3 other
risk factors
No 50 A10 5 1.5 (median
3 years)
METEOR, Crouse
et al. [54]
10-years CHD risk <10%,
moderately elevated TC
and moderate CIT
No 49–50 R40 2 5.2 (mean on trial)
CORONA, Kjekshus
et al. [55]
Systolic heart failure
and ≥60 years
No 48 R10 3 4 (at 3 months)
aCalculated from baseline data
A atorvastatin, BL baseline, CIT carotid intimal thickening, CHD coronary heart disease, HDL-C high-density lipoprotein cholesterol, HPS Heart
Protection Study, LDL-C low-density lipoprotein cholesterol, P pravastatin, R rosuvastatin, S simvastatin, TC total cholesterol, 4S Scandinavian
Simvastatin Survival Study
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rosuvastatin to have the greatest effect on both HDL-C and
apo A-I. Mean percent changes in HDL-C from baseline
across the trials weighted by patient numbers were as
follows: rosuvastatin 8.5%, pravastatin 6.5%, simvastatin
6.4%, atorvastatin 5.5%. In some but not all trials,
significant differences have been reported in the HDL-C
response to the starting doses of rosuvastatin and atorva-
statin. For example, in the largest study [68], the effect of
rosuvastatin 10 mg on HDL-C (9.2%) was significantly
greater than either atorvastatin 10 mg (6.8%, p<0.01) or
20 mg (5.7%, p<0.0001). Apo A-I responses show similar
trends between statins but are generally lower than for
HDL-C, with greater variability (Fig. 2b). Two further large
trials compared atorvastatin and simvastatin [78, 79, data
not shown]. Olsson et al. [78]( n≥535 per group) reported
notably lower HDL-C responses than in the trials described
above although the effect of simvastatin on HDL-C (3.3%)
was significantly greater than for atorvastatin (−0.1%). The
same was true of apo A-I (0.8% vs. −1.8%). However, no
difference was apparent between these statins in the study
of Barter and O’Brien [79]. Moreover, Insull et al. [80]
Fig. 2 Effects of statins given at
recommended start doses on
a high-density lipoprotein
cholesterol (HDL-C) and
b apolipoprotein A-I (apo A-I)
in hypercholesterolemic
patients. Data are shown as
mean percent change from
baseline ±95% confidence limits
when available. Number at the
base of the columns refers to the
study as indicated in the table
326 Cardiovasc Drugs Ther (2008) 22:321–338compared atorvastatin 10 mg, rosuvastatin 10 mg, and
simvastatin 20 mg and found that all increased HDL-C to
similar extents (6–7%).
In addition to those described above, 31 further trials in
hypercholesterolemic patients that included starting doses
of one or more statins met our selection criteria. In 17 of
these [74, 79, 81–95], the overall changes in HDL-C were
consistent with those shown in Fig. 2a in that they fell
within the ranges of confidence limits shown. As in the
case of Olsson et al. [78], statin trials occasionally provide
unexpectedly low or high HDL-C responses. Milionis et al.
[96] reported only a modest increase in HDL-C with
rosuvastatin 10 mg (3.3%) and a fall of 1.6% with
atorvastatin 20 mg. Negative HDL-C responses to prava-
statin have been reported [34] as well as atypically low
responses to starting doses of simvastatin [32, 38, 97–99].
In contrast, unexpected relatively large increases in HDL-C
have occasionally been reported for pravastatin 10–40 mg
[100–102], simvastatin [99, 103–105], and atorvastatin
(7.3–9.0%) [105, 106]. In two studies of particular ethnic
groups, one in African-Americans [94] and one in Hispanic-
Americans [95], HDL-C responses to rosuvastatin and
atorvastatin were consistent with Fig. 2a.
Most trials of the recommended starting doses of statins
in hypercholesterolemic patients have reported positive
effects on HDL, typically between 4% and 10% in terms
of HDL-C. There was a tendency for rosuvastatin to
provide greater increases than other statins. However, no
consistent differences are apparent between the lower and
higher starting dose of each statin.
Dose-related effects of statins on HDL up to the highest
recommended doses
Statin dose–response
Figure 3 provides an overview of the five largest studies that
measured the lipid effects of three or more doses of each
statin. The variability in HDL-C and apo A-I responses in
these trials was such that only if there had been gradients of
at least 20% with each doubling of dose would clear dose–
response relationships have been apparent. In the study of
Jones et al. [72], for example, the coefficients of variation of
percent change in HDL-C and apo A-I were approximately
200%. As evident in Fig. 3a, the confidence limits of the
estimates of percent change in HDL-C overlap between
doses in nearly all cases, making it uncertain whether or not
true dose-relationships exist over the clinical range for each
statin. The notable exception is atorvastatin, for which
change in HDL-C can be seen to decrease from the lowest
(10 mg) to the highest dose (80 mg) [72, 108, 109]. Between
atorvastatin and rosuvastatin (the two statins with greatest
effect on LDL-C), there are contrasting effects on HDL-C
such that rosuvastatin maintains a relatively constant effect
across doses whilst atorvastatin does not. Similar findings
have been provided by smaller parallel group [29], forced-
titration [110, 111] and crossover [112]t r i a l s .F o rs i m v a -
statin, even with an extended dose range of up to 160 mg,
the effects on HDL parameters did not appear to be dose-
related [112].
The lack of obvious dose–response relationships has
led to the suggestion that mechanisms different to those
regulating the LDL response must predominate in medi-
ating HDL changes [113]. However, as shown in Fig. 4,
with the important exception of atorvastatin, the HDL-C
changes observed by Jones et al. [72] do seem to parallel
those of LDL-C and TG. In Fig. 4, the regression lines are
fitted by robust MM-estimation that effectively down-
weights outliers. Notably, the data points for atorvastatin
deviate from the regression lines in a dose-related manner.
It is perfectly possible that the effect of a statin on HDL
parameters is the result of two or more competing
processes such that any relationships with dose tend to be
obscured. A tendency to increase HDL-C as a result of
reduced CETP activity due to reductions in TG might be
counteracted by negative effects due to depletion of hepatic
cholesterol consequent on inhibition of HMG-CoA reduc-
tase. According to recent experimental work in animals, the
liver could be the major source of the cholesterol that
circulates in HDL [6]. It is also possible that such
hypothetical negative effects might vary between different
statins according to the unique pharmacodynamic profile of
each compound.
This analysis suggests that with the exception of
atorvastatin, statin-induced increases in HDL-C occur in
parallel with reductions in apo B-containing lipoproteins,
but that dose relationships can be obscured by high
variability and competing effects. It is consistent however
with the view that the predominant mechanism giving rise
to statin-mediated increases in HDL-C is reduced choles-
terol ester transfer into VLDL and LDL, secondary to
reduced levels of these lipoproteins. The reason atorvastatin
does not conform to this pattern and the potential clinical
significance is a matter of current speculation.
Effects of statins at the maximal clinical doses
Figure 5 shows the HDL-C and apo A-I data from the five
largest studies (three with HDL-C as the primary endpoint)
employing the highest clinically-used doses of atorvastatin,
simvastatin and rosuvastatin. All five studies reported a
significantly lower HDL-C effect for atorvastatin compared
with other statins. Crouse et al. [115] directly compared
atorvastatin 20 mg with simvastatin 40 mg, and atorvastatin
40 mg with simvastatin 80 mg with the rationale that these
Cardiovasc Drugs Ther (2008) 22:321–338 327 327particular statin/doses were approximately matched with
respect to LDL-C reduction. Atorvastatin increased HDL-C
significantly less than simvastatin in both comparisons, a
finding confirmed by Kastelein et al. [116], and significant
differences in apo A-I were also observed in the higher-
dose comparative pair. In other randomized, double-blind
trials of high-dose statin therapy, Smilde et al. [120]
showed similar HDL-C increases for atorvastatin 80 mg
and simvastatin 40 mg, while Ballantyne et al. [117]
reported a significantly lower increase in HDL-C with
atorvastatin 80 mg compared with simvastatin 80 mg, the
effect of atorvastatin on apo A-I being slightly negative.
Leiter et al. [119], compared rosuvastatin 40 mg with
atorvastatin 80 mg, and found significantly greater
increases in both HDL-C and apo A-I with rosuvastatin
(9.6% and 4.2%, respectively) than atorvastatin (4.4% and
0.5%, respectively). Similar findings were reported in a
forced-titration study of these two statins [121].
The percentage change in HDL-C induced by statins is
usually greater in patients with lower than in those with
higher baseline HDL-C levels. For example, Ballantyne et
al. [117] reported greater HDL-C changes with baseline
HDL-C <40 vs. ≥40 mg/dl when patients were treated with
simvastatin 80 mg or atorvastatin 80 mg. Patients with
acute coronary syndromes tend to have low HDL-C levels
and in these, the HDL-C increases with statins were
relatively high [122].
Comparisons between statins given at the higher doses
consistently show atorvastatin to have a lesser effect on HDL
compared to simvastatin or rosuvastatin, in line with the dose-
relatedeffectsdiscussedearlier.PercentagechangesinHDL-C
are greater in patients with initially lower baseline values.
Fig. 3 Dose-related effects of
statins on a high-density lipo-
protein cholesterol (HDL-C) and
b apolipoprotein A-I (apo A-I)
in hypercholesterolemic patients
in five studies. Data are shown
as mean percent change from
baseline ±95% confidence limits
when available. Dose (mg) is
shown at the base of each
column
328 Cardiovasc Drugs Ther (2008) 22:321–338Effect of statins compared with other drugs
that raise HDL
Fibrates are generally more effective than statins in lowering
plasma TG and are used primarily in patients with elevated
TG levels. Through their agonist action on PPARα, fibrates
alter the expression and activity of genes involved in lipid
metabolism, in particular increasing the hepatic synthesis of
apoA-I[123]. Fibrates can reduce LDL, to a limited degree,
but usually have a considerably greater effect on HDL than
statins. This may be due both to the direct effect of
increased entry of apo A-I into the circulation and to the
indirect effect of reduction in VLDL-TG. For example, in a
24-week trial comparing gemfibrozil 600 mg twice daily
with pravastatin 40 mg/d in patients with familial or
polygenic hypercholesterolemia, TG <250 mg/dl and
relatively normal HDL-C levels, pravastatin as expected
lowered LDL-C more than gemfibrozil but had lesser effect
on HDL-C (5% vs. 13%, respectively, p<0.01), although
changes in apo A-I were similar (8% vs. 7%, respectively)
[124]. Similar differences were reported for these compa-
rators by Wiklund et al. [35]. Superior effects on HDL-C
favoring the fibrate have also been reported between
gemfibrozil and simvastatin [125], bezafibrate and simva-
statin [126], and micronized fenofibrate and pravastatin
[127]. Two studies reported similar effects when comparing
fenofibrate and simvastatin [128, 129]. The latter study
found particularly high HDL-C responses (18% vs. 15%,
respectively), the reason for which is unclear. Nicotinic acid
(niacin) is a long-established therapy with modest effect on
LDL but substantial impacts on TG and HDL. Depending
upon the type of hyperlipidemia and baseline HDL-C,
extended-release niacin can increase HDL-C by up to 30%
and decrease TG levels by 40–50% [130, 131].
Unprecedented increases in HDL-C and apo A-I levels
have been observed in phase II trials of the newly
developed direct inhibitors of CETP. For example, in
patients with low HDL-C levels, 4 weeks of treatment with
torcetrapib 120 mg twice daily increased HDL-C from 34 to
70 mg/dl (106%) and apo A-I from 112 to 151 mg/dl (36%)
[132], considerably greater increases than seen with statins,
fibrates, or nicotinic acid. However, recent imaging and
outcomes studies with torcetrapib in combination with
atorvastatin have not indicated any beneficial impact upon
atherosclerosis or cardiovascular morbidity and mortality,
possibly due to a unique adverse effect of torcetrapib on
aldosterone, electrolytes, and blood pressure [20–22, 133].
Fibrates and nicotinic acid increase HDL-C and lower
TG usually to a greater extent than statins but their impact
on LDL-C is considerably less. They are most useful in
patients with hypertriglyceridemia. Direct inhibitors of
CETP cause the greatest increases in HDL-C but the
clinical value of this mechanism is currently unknown.
Effects of statins combined with other drugs on HDL
in patients with hypercholesterolemia
Bile acid sequestrants such as cholestyramine and inhibitors
of cholesterol absorption such as ezetimibe reduce levels of
atherogenic lipoproteins albeit to a lesser degree than
statins. Nevertheless, these agents can be effective in
combination with statins, providing incremental reductions
in LDL-C in cases of severe hypercholesterolemia and
resistance to statin therapy. When used alone, these agents
Fig. 4 Relationships between mean percent changes in high-
density lipoprotein cholesterol (HDL-C) and mean percent changes
in a triglycerides (TG)a n db low-density lipoprotein cholesterol
(LDL-C) in the STELLAR study [72]. Dashed lines calculated by a
robust MM estimation. Panel a taken from Jones et al. [114]
Cardiovasc Drugs Ther (2008) 22:321–338 329 329produce small increases (5–8%) in HDL-C [29, 30, 33, 103,
134]. However, while cholestyramine and pravastatin in
combination provided a greater reduction in LDL-C than
either monotherapy, there was no additive effect on HDL-C
[33, 135]. Two 12-week studies compared the full range of
simvastatin doses with and without ezetimibe 10 mg. The
larger study [30]( n≥156 per group) found no significant
additive effect of ezetimibe on HDL-C whilst the smaller
study [29]( n≥52 per group) showed a modest but
significant 2.4% (p<0.05) increment averaged across doses.
Similar rather modest incremental HDL-C effects of
ezetimibe with statins were reported by Feldman et al.
[136] and Ballantyne et al. [137, 138]. In these studies there
was little evidence of any additive effects on apo A-I.
Ballantyne et al. [108, 139] compared the full range of
simvastatin doses in combination with ezetimibe to those of
atorvastatin alone and found, at the 40 and 80 mg doses, a
significantly greater effect on HDL-C with the simvastatin
combination, which was attributed to the attenuation of
the HDL-C response at higher doses described earlier.
Catapano et al. [107] compared the ezetimibe/simvastatin
combination in the range 10/20 to 10/80 mg with
rosuvastatin 10/40 mg and found no difference in the
HDL-C responses to those of the rosuvastatin monotherapy
(7% to 8%). In summary, the addition of either bile acid
sequestrants or inhibitors of cholesterol absorption provides
at best only modest increments in the HDL-C response
to statins.
Fig. 5 Effects of statins at the
maximal clinical doses on
a high-density lipoprotein cho-
lesterol (HDL-C) and b apoli-
poprotein A-I (apo A-I)i n
hypercholesterolemic patients.
Data shown as mean percent
change from baseline ±95%
confidence limits when avail-
able. Dose (mg) is shown given
at the foot of each column
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syndrome, and T2D
In many individuals, low HDL-C levels (<40 mg/dl men;
<50 mg/dl women) are associated with elevated TG levels,
which, in turn, are common in obesity, insulin resistance,
metabolic syndrome, and T2D [140]. As noted above, there
is a well-established inverse correlation between TG and
HDL-C [56] and the combination of high TG, low HDL,
and abnormal LDL (small-dense LDL), often called the
“lipid triad”, is particularly prevalent in these conditions
and thought to be strongly atherogenic [141]. Indeed, the
linkage of HDL-C levels to these associated abnormalities
of atherogenic lipoproteins may explain much of the
predictive power of HDL-C.
Elevated triglycerides and mixed hyperlipidemia
Fibrates and nicotinic acid are the drugs of choice in severe
hypertriglyceridemia. However, in mixed hyperlipidemia,
when both TG and LDL are elevated, statins can provide a
logical alternative as they are very effective in reducing
LDL-C and can also lower TG. This point is supported by a
number of studies [142–146]. The study by Grundy et al.
[144] exemplifies the efficacy of a statin-fibrate combina-
tion in mixed hyperlipidemia. With simvastatin 20 mg
together with fenofibrate 160 mg, HDL-C and apo A-I
increased by 19% and 9% vs. 10% and 5% with statin
alone. In a similar population, Farnier et al. [147] found that
a combination of simvastatin 20 mg, fenofibrate 160 mg,
and ezetimibe 10 mg raised HDL-C and apo A-I by 19%
and 11% respectively. With both statins and fibrates, the
increases in HDL-C generally reflect the reductions in
VLDL-TG, suggesting reduced CETP-mediated flow of
cholesteryl ester from HDL to VLDL as a major link
between the HDL effects of statins and fibrates. Interest-
ingly however, HDL size increased with simvastatin (3%)
but not with gemfibrozil, hinting that there are differences
as well as similarities in the mechanisms involved with the
two classes of drugs.
Metabolic syndrome
Attention has increasingly focused on the effects of statins
in ameliorating the high risk of CHD in patients with
metabolic syndrome. Raised TG and low HDL-C represent
two of five National Cholesterol Education Program
(NCEP) criteria defining the metabolic syndrome [11]. In
a placebo-controlled study of patients with metabolic
syndrome so defined, atorvastatin 10 mg increased HDL-C
by 5.1% and rosuvastatin 10 mg by 9.5% (p<0.01 between
treatments) compared with +1% for placebo [148]. There
were corresponding but lesser changes in apo A-I. Similar
increases in HDL-C have been seen in metabolic syndrome
subgroups from larger trials [110, 149].
Diabetes
T2D carries a high risk of CHD. Statin therapy substantially
reduces this risk and they are now the standard of care [150].
Evidence from trials of statins in this condition suggests that
the degree of statin-induced change in HDL parameters
depends on the baseline TG and HDL-C levels. For example,
the study of Stein et al. [151] included patients with T2D and
mixed hyperlipidemia having relatively high TG (median
391 mg/dl) and low HDL-C (mean 39 mg/dl) at baseline.
After 6 weeks of treatment with simvastatin 40 or 80 mg/d,
the increases in HDL-C were substantial: 13% and 16%
compared to 3.3% with placebo; the corresponding changes
in apo A-I were 8.2%, 10%, and 4.0%. In similar
populations, Durrington et al. [152] observed that rosuva-
statin 5 or 10 mg elevated HDL-C by 9.9% and 10%
compared with 1.2% for placebo while Gentile et al. [153]
recorded increments in HDL-C of 7.1–7.4% with atorva-
statin, simvastatin, and pravastatin (each 10 mg/d) and a
slight reduction with placebo. In T2D subjects with a
baseline HDL-C <40 mg/dl (mean 34 mg/dl), Miller et al.
[154] found HDL-C increases of 4.8% and 8.5% with
simvastatin 40 and 80 mg, vs. a slight reduction with
placebo. In contrast, in T2D study populations with relatively
normal TG and HDL-C at baseline, the statin-induced
HDL-C responses were usually relatively less as reported
by Schweitzer et al. [155] and by Schuster et al. [68].
Moreover, in two large-scale outcome studies evaluating the
effects of atorvastatin 10 mg in these patients, there were
only non-significant changes in HDL-C (1–2%) and TG
(−4% to −19%) [156, 157]. There has been only one study of
patients with T2D that has recorded a substantial HDL-C
response to atorvastatin (17%), but this compared to a 13%
change with placebo [158]. In contrast to the many studies of
statins in patients with T2D, relatively few have been
performed in type 1 and none matched our selection criteria.
Statins are effective in raising HDL-C in mixed hyper-
lipidemia, metabolic syndrome, and T2D, but this seems to
be dependent on baseline parameters. Statins are less
effective than fibrates in raising HDL-C in these conditions
but achieve much greater LDL-C reductions. The evidence
suggests that combination of a statin with a fibrate may
provide benefits both on LDL and on the TG-HDL axis.
Effects of statins on HDL over the longer-term
and the relationship with clinical benefit
Data from placebo-controlled trials of long duration
(Table 1) suggest that the effects of statins on HDL are
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HDL effects between statins are also maintained is more
difficult to answer, as few long-term trials have made such
comparisons. However, the relatively attenuated HDL
effect of high dose atorvastatin has been observed in long-
term studies. In a double-blind comparison of atorvastatin
80 mg and pravastatin 40 mg [159], the percentage
increases in HDL-C from baseline at 18 months were
2.9% and 5.6% respectively. An absolute difference in
HDL-C levels of 1.2–1.9 mg/dl between the groups treated
with simvastatin 20 mg or atorvastatin 80 mg (in favor of
the former) was reported to be maintained over 4 years in
the study of Pedersen et al. [160], although the difference
diminished in the fifth year of observation. Similarly, in
acute coronary syndrome patients, there was a difference of
1.6% in HDL-C levels between pravastatin 40 mg and
atorvastatin 80 mg over a 2-year period, Cannon et al.
[122]. However, there was no difference in this respect
between 10 mg and 80 mg of atorvastatin over 5 years [66].
Statin treatment reduces coronary events in patients with
low HDL-C levels [161–163]. Moreover, HDL-C levels
continued to predict cardiovascular risk even when LDL-C
was reduced to very low levels by atorvastatin [164].
However, the respective contribution made by statin-
induced increases in HDL-C to cardiovascular benefit is
not always apparent from clinical trial data. This may be
due to considerable inter-individual differences (depending
in turn on the particular combination of risk factors and
genetic predisposition) in the degree to which a change in
HDL impacts upon disease progression and perhaps most
importantly to the overwhelming positive effect of reduc-
tions in LDL. In the outcome studies mentioned above in
which statins were compared, the differences in HDL-C
responses due to pravastatin in Cannon et al. [122] and
simvastatin in Pedersen et al. [160] did not outweigh the
superior LDL-C reductions due to atorvastatin 80 mg. The
potential contributions made to outcomes by statin-induced
changes in HDL-C are best discerned in the large scale such
as in the Pravastatin Pooling Project, which combined data
from three large trials of pravastatin 40 mg [162]. As
expected, baseline LDL-C and HDL-C levels, analyzed in
quintiles, were strongly predictive (positively and nega-
tively, respectively) of events in the placebo group. In the
treated group, the slope of the line relating baseline LDL-C
to risk was markedly reduced, indicating the statin had
markedly ameliorated LDL-associated risk. In contrast, the
slope of the HDL-C line was only slightly reduced
indicating a rather modest effect on the HDL-associated
risk. This might be expected given that the effect of the statin
on LDL was greater (−25% to −28%) than that on HDL-C
(5%). Post hoc analysis of data from the Scandinavian
SimvastatinSurvivalStudy(4S)byCoxProportionalHazard
suggested an independent benefit of the simvastatin effect on
HDL-C,a reductioninrisk of0.8% foreach 1% increase [42,
161]. The application of other statistical models also found
significant or marginally significant independent benefit
arising from the increases in HDL-C. In an additional post
hoc analysis of the 4S study, Ballantyne et al. [165] found
that the subgroup defined as having HDL-C in the lowest
and TG in the highest quartile had the most substantial
event reduction.
In order to address this issue with respect to progression
or regression of coronary atherosclerosis, Nicholls et al.
[166] combined data from four trials that used intravascular
ultrasound to measure atheroma volume. In multivariate
analyses, as expected, the on-treatment LDL-C was
correlated with the atheroma parameters, but the change in
HDL-C (but not the on-treatment value) also made a strong
independent contribution. Notably, participants who
showed lesion regression manifested not only a low on-
treatment LDL-C but also an HDL-C increase greater than
the overall mean of 7.5%. There are some weaknesses in
this post hoc analysis. For example in two of the pooled
trials, statin therapy was unrandomized background treat-
ment, all four trials were open-label and there were no
placebo groups. Thus, while an association between change
in HDL-C and reduced atherosclerosis progression was
apparent, a direct, HDL-mediated causal effect of statins
cannot be directly inferred. In a meta-analysis of 23
placebo-controlled trials with clinical cardiovascular end-
points, Brown et al. [167] found the best model to describe
either change in stenosis or change in event rate involved
the simple addition of percentage changes in LDL-C and
HDL-C (R
2, 0.93 and 0.96, respectively), but it was not
determined if the relationships between these two parame-
ters and stenosis or risk were independent of one another.
With statins, the impact of reduction in the apo B-
containing lipoproteins on atherosclerosis and cardiovascu-
lar events is sure to be greater than that due to any changes
in HDL levels. Nevertheless, given the strength and
independence of the epidemiologic relationships, it is
reasonable to expect that statin-induced elevations in HDL
make an independent contribution to benefit. It would be
difficult to conceive a clinical outcomes trial that would
provide absolute verification of this hypothesis. It would be
necessary to compare statins in such a way that LDL-C
levels were the same between groups (and equivalent in
terms of other potential ‘pleiotropic’ effects), allowing only
HDL-C responses to differ. However, as noted earlier,
statins increase HDL parameters and lower TG, altering the
HDL subpopulations in a way consistent with clinical
benefit. The evidence related above lends some support to
this hypothesis. Moreover, it is reasonable to expect that the
degree of HDL-associated benefit of statins is proportional
to the change in HDL levels. It is important therefore to
assess statins not only in terms of their capacity to reduce
332 Cardiovasc Drugs Ther (2008) 22:321–338LDL and VLDL but also their respective abilities to raise
levels of HDL.
Summary and conclusions
The development of statins capable of profound reductions
in the levels of apo B-containing atherogenic lipoproteins
has been a major advance in cardiovascular medicine. In
this respect, the statins have been thoroughly investigated
and their within-class differences in, for example, the dose-
related effects on LDL-C are well documented [72].
However, in view of the strong relationships between levels
of HDL and cardiovascular risk, it is also important to
understand the manner and degree of statin effects on these
lipoproteins and whether there are important differences
between them in this respect. However, most clinical trials
of statins have not been set up with such aims in mind and
have been underpowered with respect to HDL parameters.
The purpose of this review has been to draw together in a
systematic way all of the information about changes in
HDL available from clinical trials that met certain prede-
fined qualitative and quantitative criteria.
The data from placebo-controlled trials clearly demon-
strated that statins induce real increases in both HDL-C and
apo A-I. The increases in HDL-C were about twice those of
apo A-I, consistent with specialized studies that have
demonstrated alterations of HDL subpopulations towards
larger more cholesterol-rich forms characteristic of healthy
low-risk populations with low TG and high HDL-C.
However, the changes in HDL parameters induced by
statins are limited in comparison to fibrates and nicotinic
acid. Percentage increases are usually greater in those with
lower baseline levels. The data from the large morbidity
and mortality trials suggested that the statin-induced effects
on HDL-C and apo A-I were maintained over time.
Moreover, analysis of the covariates of the HDL-C changes
observed in these large studies suggested that CETP
activity was a key factor that determines those changes.
This makes it likely that the main mechanism of the
elevations in HDL-C is a reduced rate of transfer of
cholesterol from HDL to the apo B-containing lipoproteins
consequent on the profound reductions in the latter. In
hypercholesterolemic patient populations, the usual starting
doses of statins provide increases in HDL-C of between 4%
and 10%. There was a tendency for rosuvastatin to elevate
HDL-C more than the other statins (atorvastatin, simva-
statin, and pravastatin). In contrast to their effects on LDL-C
and apo B, statins do not show clear-cut dose-response
relationships with respect to HDL-C and apo A-I. However,
further analysis of the largest dose–response study did
indicate that the degree of change in HDL-C was partly
related to the degree of reduction in TG and LDL-C,
consistent with the suggested CETP-related mechanism.
However, atorvastatin was a notable exception, in that there
was an inverse dose-relationship with diminishing effects on
HDL parameters with increasing dose. Comparisons at the
highest clinical doses consistently showed atorvastatin to
have the least effect on HDL parameters compared with the
other three statins. In patients with mixed dyslipidemia,
having high TG and low HDL-C as well as elevated LDL-C,
statins induce more substantial percentage increases, and a
combination of statin and fibrate provides optimal normal-
ization of lipoprotein levels, including HDL.
The main cardiovascular benefits of statins are un-
doubtedly due to the major reductions of LDL and the
other atherogenic lipoproteins. However, it is reasonable to
suggest that increases in HDL may also make a valuable
contribution to benefit since some of the data from the
morbidity and mortality trials, as well as from imaging
studies support this hypothesis. However, the independent
contributions of the changes induced by statins on LDL and
HDL remains an area that requires further study and
clarification.
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